首页> 外文OA文献 >PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

【2h】

PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

机译：PND32 - 在巴西公共医疗系统中的可用干扰素的多发性硬化第一线治疗的成本比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J Rigolon; LF Conceição;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs [J] . James D Bowen, Chris M Kozma, Megan M Grosso, Multiple Sclerosis Journal ?C Experimental, Translational and Clinical . 2018,第4期

机译：新近开始使用皮下干扰素β-1a的多发性硬化患者与口服疾病改善药物的复发率，医疗保健费用和资源使用的现实比较
2. COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE AS A FIRST SWITCH TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM [J] . Fahham L., Murta L., Teich V, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第3期

机译：富马酸二甲酯作为缓解巴西公共卫生系统多发性硬化的首次开关的成本效用分析
3. COST PER RESPONDER ANALYSIS OF USTEKINUMAB VERSUS SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE [J] . Araujo R. L., Scaccabarozzi L., Asano E. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Ustekinumab与Secukinumab对巴西公共医疗系统视角下适度至严重牛皮癣的每次响应性分析
4. The Treatment Profile of a "Upa" and the Impact on Brazilian Public Healthcare [C] . Maximo, L.M.I., Queiroz, World Congress on Public Health . 2013

机译：“upa”的治疗概况和对巴西公共医疗保健的影响
5. The Impact of Health Insurance Status on Healthcare Resource Utilization and Out-of-Pocket Costs in Patients with Multiple Sclerosis in the U.S.A [D] . Elsisi, Zizi. 2020

机译：健康保险状况对患有多发性硬化患者的医疗资源利用和U.S.A的患者的影响
6. A real-world comparison of relapse rates healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs [O] . James D Bowen, Chris M Kozma, Megan M Grosso, 2018

机译：新近开始使用皮下干扰素β-1a的多发性硬化患者与口服疾病改善药物的复发率医疗保健费用和资源使用的现实比较
7. PND20 Budget Impact of Chosing Rebif® as the Interferon of Choice for the Treatment of Relapsing-Remitting Multiple Sclerosis In the Brazilin Public Healthcare System [O] . Fujii R.K., Wong S., Junqueira M. 2015

机译：PND20在巴西公共医疗体系中选择Rebif®作为治疗复发缓解型多发性硬化症的首选干扰素的预算影响

PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

著录项

引文网络

相似文献

相关主题

期刊订阅